Piramal expands its high potency API capability

25 Jun 2019

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

CDMO Piramal Pharma Solutions (PPS) has opened a new wing at its Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs). The total investment required to upgrade the site was approximately $10 million, which includes a new QC/analytical lab and two kilo-labs, as well as a doubling of the office space, which was needed to support the dramatic growth at the Riverview site.

Piramal expands its high potency API capability

To date, the Riverview site has had the containment capability and engineering controls to safely handle HPAPIs with OELs down to 1 mcg/m3, at scales ranging from grams to approximately 250 kilos. The new wing, which consists of two kilo-labs and a QC/analytical lab, brings more to the table. It has been designed with the required engineering controls and containment solutions to handle HPAPIs with OELs <1 mcg/m3 and as low as approximately 20 ng/m3. Materials will primarily be produced in this new wing at kilo-lab scales; lots of <5 kilos can be produced in this new state-of-the-art facility.

Vivek Sharma, CEO, Piramal Pharma Solutions said: “We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs. It’s another example of how we remain committed to partnering with our customers to serve the patient community and reduce the burden of disease.”

Historically, the site operated as one shift, 5 days a week. Today, the site operates 12 hours a day, 7 days a week, and is headed towards being a full 24/7 site. The Riverview site expansion also provides significant benefits to the local economy, including the addition of new high-tech jobs. The local staff has increased from 80 to 127 people, with a projected total of approximately 150 employees in the near future. This includes high-tech staffing of PhD and BS degreed scientists, plus manufacturing operators and other skilled workers.

Vince Ammoscato, Vice President and Riverview Site Head, added: “This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market. We are equipped to offer ADC customers a seamless end-to-end solution since we can develop the HPAPI payloads and linkers here in Riverview, send them to our site in Scotland for the antibody conjugation, then back to our Lexington, Kentucky site for sterile fill and finish.”

The ability to offer a fully integrated solution for the ADC market – from proof-of-concept studies to conjugation development, clinical and commercial ADC GMP batch manufacturing and fill/finish – represents a significant strategic advantage for Piramal Pharma Solutions.

According to Mr Ammoscato, more expansions are forthcoming. There is additional real estate available on the site for added capacity and new capability enhancements that will be designed to match the market needs of the pharmaceutical industry.

Read More

Related news

CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
AI to deliver next evolution of drug manufacturing and supply chain efficiency

AI to deliver next evolution of drug manufacturing and supply chain efficiency

9 Jun 2020

Webinar will help manufacturers to harness the advantages of using real-time analytics to enhance performance and reduce waste.

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
Rescheduled CPhI South East Asia moved to November

Rescheduled CPhI South East Asia moved to November

4 May 2020

Second postponement will provide improved confidence and market conditions for exhibitors and visitors.

Read more 
New technologies for solid dosage forms from Syntegon

New technologies for solid dosage forms from Syntegon

28 Apr 2020

Syntegon's new coater series can handle tablets with highly potent active ingredients.

Read more 
CPhI & P-MEC China moves to December to enable international attendance

CPhI & P-MEC China moves to December to enable international attendance

21 Apr 2020

Date alteration taken at the request of exhibitors to ensure the international character of China’s largest pharma exhibition.

Read more 
2020 CPhI Pharma Awards are open for entries

2020 CPhI Pharma Awards are open for entries

21 Apr 2020

Submit your entry before 1 July 2020!

Read more 
The future of liquid pharmaceutical processing on show ... virtually!

The future of liquid pharmaceutical processing on show ... virtually!

20 Apr 2020

Syntegon to showcase flexible solutions for small and microbatches, new developments for liquid filling and assembly, as well as AI-enhanced product safety.

Read more 
CPhI announces new pharma events calendar for 2020

CPhI announces new pharma events calendar for 2020

17 Mar 2020

Organizers secure three new dates for events in Japan, South East Asia and North America in response to COVID-19.

Read more 
CPhI Japan 2020 Postponed

CPhI Japan 2020 Postponed

27 Feb 2020

Rescheduling will ensure all stakeholders can take part in a successful exhibition and conference.

Read more